ArticleDermatology (Basel, Switzerland)2026
Atopic disease prevalence by nativity, citizenship, and years of residence in the United States.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough atopic disease, including atopic dermatitis (AD), asthma, and allergic rhinitis, is less prevalent among immigrants than natives in developed nations, its prevalence is poorly characterized among US immigrants. In this study, we investigated the individual and joint effects of nativity, US citizenship, and duration of US residence on the prevalence of atopic disease among US adults.
methodsWe analyzed 25,597 US-born and 4,714 immigrant sample adults from the 2024 National Health Interview Survey. We generated nationally-representative prevalence estimates and fitted sociodemographic-adjusted multivariable logistic regression models.
resultsCompared to US-born individuals, immigrants reported less AD (4.5% vs 8.5%; aOR: 0.56, 95% CI: [0.45-0.70]). Noncitizens also reported less AD (aOR: 0.38 [0.28-0.52]) than citizens. Moreover, compared to US-born participants, immigrant noncitizens (2.5%; aOR: 0.33 [0.23-0.45]) reported less AD than immigrant citizens (6.2%; aOR: 0.68 [0.54-0.87]). Compared to US-born participants, immigrants residing <15 years in the US (4.2%; aOR: 0.47 [0.32-0.69]) reported less AD than immigrants with ≥15 years of residence (4.7%; aOR: 0.60 [0.48-0.75]); longer US residence may erode the protective effect of immigration via immigrants' gradual adoption of US-specific health behaviors, including proinflammatory diets and obesity, increasing AD risk. In joint stratification analysis, AD prevalence increased progressively from recent immigrant noncitizens (2.7%; aOR: 0.30 [0.19-0.45]) to long-term immigrant citizens (5.7%; aOR: 0.64 [0.51-0.81]), and ultimately US-born citizens (8.5%; reference level), suggesting a dose-dependent relationship between acculturation and AD risk. Study limitations include self-reported outcomes. Results were similar for asthma, allergic rhinitis, and overall atopic disease.
conclusionsEarly-life environmental exposures abroad may promote immune profiles associated with reduced AD risk. Longer US residence may erode the protective effect of immigration via immigrants' gradual adoption of US-specific health behaviors, including proinflammatory diets and obesity, increasing AD risk. Our results demonstrate a dose-dependent relationship between acculturation and atopic disease risk. Study limitations include self-reported outcomes. Citizenship demonstrated greater differences in outcomes than duration of US residence, suggesting it may capture additional factors influencing variation in atopic disease and merits further study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.